T1

The term "T1" is a non-specific identifier used in various clinical and research contexts. In the provided excerpts, "T1" refers to at least two distinct pharmaceutical formulations: a specific low-dose (1.25 mg) inhalation of Epinephrine Inhalation Aerosol USP (E004) in a pharmacokinetic study for asthma (NCT01143051), and a test formulation of Hemay005 Tablets in a bioequivalence study for psoriasis (NCT06610903). Beyond drug-related contexts, "T1" frequently denotes a time point for data collection or intervention in clinical trials (e.g., NCT06500728, NCT03291132, NCT06779357, NCT07182019, NCT03681821, NCT03684525, NCT04346303), a stage of various cancers (e.g., bladder, renal cell, colorectal) (NCT05375903, NCT03624673, NCT03588416), Type 1 Diabetes (NCT00945711, NCT00451321), or a parameter in Magnetic Resonance Imaging (T1-mapping, T1 relaxometry) (NCT05239260, NCT02764619, NCT05177523). It can also refer to a medical procedure, such as the "three-target GNRFA technique" for knee osteoarthritis (NCT05930756).